link from in-pharma-tech
20/06/2005 - US biotechnology company Biogen Idec has said that it plans to sell a California manufacturing plant built to produce its withdrawn multiple sclerosis drug Tysabri (natalizumab) to Genentech, reports Phil Taylor.
Maybe the plant needs to be converted to produce the other product!!!
Friday, June 24, 2005
Genentech buys Biogen Idec plant for $408m
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment